Tirzepatide and donanemab set to outshine market rivals, says analyst

17 April 2024

US pharma major Eli Lilly (NYSE: LLY) is on the brink of reshaping the pharmaceutical landscape with its ground-breaking treatments, Mounjaro (tirzepatide) for diabetes and marketed as Zepbound for obesity and the highly anticipated donanemab for early symptomatic Alzheimer’s disease.

According to pharma analytics company GlobalData, both of the drugs are poised to exceed market expectations and challenge existing industry leaders, marking significant milestones in Lilly’s journey towards market dominance,

Mounjaro has already made a notable impact in the treatment of obesity and type 2 diabetes, positioning Lilly as a key player against Denmark-based Novo Nordisk’s (NOV: N) Wegovy (semaglutide).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK